8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Astrana Health, Inc.(ASTH)Earnings, Financials & Key Ratios
ASTH•NASDAQ
85.2× P/E·Price updated Jun 19, 2026
AboutAstrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.Show more
- Revenue$3.18B+56.4%
- EBITDA$124M+6.0%
- Net Income$22M-47.9%
- EPS (Diluted)0.46-48.9%
- Gross Margin9.3%-30.3%
- EBITDA Margin3.91%-32.2%
- Operating Margin2.47%-43.8%
- Net Margin0.71%-66.7%
- ROE4.19%-55.1%
ASTH Key Insights
Astrana Health, Inc. (ASTH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 53.8%
- ✓Trading near 52-week high
- ✓Efficient asset utilization: 1.4x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ASTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASTH Price & Volume
Astrana Health, Inc. (ASTH) stock price & volume — 10-year historical chart
Loading chart...
ASTH Growth Metrics
Astrana Health, Inc. (ASTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years53.76%
3 Years40.62%
TTM56.69%
Profit CAGR
10 Years-
5 Years-
3 Years-20.75%
TTM-13.64%
EPS CAGR
10 Years-
5 Years-14.55%
3 Years-22.55%
TTM-16.78%
Return on Capital
10 Years4.87%
5 Years10.87%
3 Years9.2%
Last Year6.06%
ASTH Recent Earnings
Astrana Health, Inc. (ASTH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.74+155.2%
$0.29
Rev
$965M+1.7%
$949M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.54+260.0%
$0.15
Rev
$951M+2.2%
$930M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.01-97.9%
$0.47
Rev
$956M+2.7%
$930M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.19-47.2%
$0.36
Rev
$655M-30.6%
$944M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.74vs $0.29+155.2% | $965Mvs $949M+1.7% |
| Q2 2026 | Mar 2, 2026 | $0.54vs $0.15+260.0% | $951Mvs $930M+2.2% |
| Q4 2025 | Nov 6, 2025 | $0.01vs $0.47-97.9% | $956Mvs $930M+2.7% |
| Q3 2025 | Aug 7, 2025 | $0.19vs $0.36-47.2% | $655Mvs $944M-30.6% |
Based on last 12 quarters of dataView full earnings history →
ASTH Peer Comparison
Astrana Health, Inc. (ASTH) competitors in Physician platforms and value-based care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALHC | 4.47B | 21.86 | -5908.11 | 46.06% | 0.47% | 11.5% | 1.89 | |
 CLOV | 2.59B | 5.00 | -29.41 | 40.34% | -2.58% | -17.08% | ||
 OSCR | 7.36B | 28.40 | -16.80 | 27.5% | -0.3% | -3.26% | 0.44 | |
 WELL | 144.78B | 206.65 | 148.67 | 35.82% | 12.31% | 3.49% | 0.49 | |
 AGL | 1.9B | 113.80 | -4.64 | -2.11% | -6.42% | -146.01% | 0.29 | |
 DOCS | 3.83B | 20.46 | 20.88 | 13.05% | 30.4% | 19.36% | 0.01 | |
 PRVA | 2.98B | 23.67 | 131.50 | 22.26% | 0.97% | 0.01% | 0.01 | |
 UNH | 363.94B | 400.96 | 30.31 | 11.81% | 2.68% | 11.54% | 0.77 |
Compare ASTH vs Peers
Astrana Health, Inc. (ASTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASTH Income Statement
Astrana Health, Inc. (ASTH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 357.75M | 519.91M | 560.62M | 370.25M | 773.91M | 1.14B | 1.39B | 2.03B | 3.18B | 3.53B |
Revenue Growth % | 712.16% | 45.33% | 7.83% | -33.96% | 109.03% | 47.84% | 21.19% | 46.72% | 56.39% | 56.69% |
Cost of Goods Sold | 293.73M | 380.44M | 467.81M | 348.54M | 596.14M | 944.68M | 1.17B | 1.76B | 2.89B | 3.2B |
COGS % of Revenue | 82.11% | 73.17% | 83.44% | 94.14% | 77.03% | 82.57% | 84.5% | 86.66% | 90.7% | - |
Gross Profit | 64.02M▲ 0% | 139.47M▲ 117.9% | 92.81M▼ 33.5% | 21.7M▼ 76.6% | 177.77M▲ 719.0% | 199.48M▲ 12.2% | 214.96M▲ 7.8% | 271.39M▲ 26.3% | 295.78M▲ 9.0% | 328.47M▲ 0% |
Gross Margin % | 17.89% | 26.83% | 16.56% | 5.86% | 22.97% | 17.43% | 15.5% | 13.34% | 9.3% | 9.31% |
Gross Profit Growth % | 560.19% | 117.87% | -33.45% | -76.61% | 719.04% | 12.21% | 7.76% | 26.25% | 8.99% | - |
Operating Expenses | 26.44M | 47.24M | 60.39M | 15.62M | 79.59M | 95.21M | 130.34M | 182.04M | 217.26M | 242M |
OpEx % of Revenue | 7.39% | 9.09% | 10.77% | 4.22% | 10.28% | 8.32% | 9.4% | 8.95% | 6.83% | - |
Selling, General & Admin | 26.44M | 47.24M | 41.48M | 15.59M | 62.08M | 77.67M | 112.6M | 154.11M | 217.26M | 235.1M |
SG&A % of Revenue | 7.39% | 9.09% | 7.4% | 4.21% | 8.02% | 6.79% | 8.12% | 7.57% | 6.83% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 18.91M | 26K | 17.52M | 17.54M | 17.75M | 27.93M | 0 | 1000K |
Operating Income | 37.58M▲ 0% | 92.23M▲ 145.4% | 32.42M▼ 64.8% | 6.09M▼ 81.2% | 98.18M▲ 1513.2% | 104.27M▲ 6.2% | 84.61M▼ 18.8% | 89.35M▲ 5.6% | 78.53M▼ 12.1% | 86.47M▲ 0% |
Operating Margin % | 10.5% | 17.74% | 5.78% | 1.64% | 12.69% | 9.11% | 6.1% | 4.39% | 2.47% | 2.45% |
Operating Income Growth % | 670.91% | 145.44% | -64.85% | -81.23% | 1513.19% | 6.2% | -18.85% | 5.6% | -12.12% | - |
EBITDA | 56.65M | 111.53M | 50.7M | 24.44M | 115.7M | 121.81M | 102.36M | 117.28M | 124.27M | 140.85M |
EBITDA Margin % | 15.84% | 21.45% | 9.04% | 6.6% | 14.95% | 10.65% | 7.38% | 5.76% | 3.91% | 3.99% |
EBITDA Growth % | 1009.26% | 96.87% | -54.54% | -51.8% | 373.47% | 5.28% | -15.97% | 14.57% | 5.97% | 28.66% |
D&A (Non-Cash Add-back) | 19.08M | 19.3M | 18.28M | 18.35M | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M | 54.38M |
EBIT | 49.79M | 83.19M | 30.57M | 11.39M | 83.14M | 94.54M | 105.94M | 113.92M | 78.53M | 94.52M |
Net Interest Income | 935.51K | 698K | -2.71M | -2.12M | -3.82M | -5.94M | -1.89M | -18.59M | -37.77M | -45.06M |
Interest Income | 1.02M | 1.26M | 2.02M | 405K | 1.57M | 1.98M | 14.21M | 14.51M | 12.16M | 13.66M |
Interest Expense | 79.69K | 560.51K | 4.73M | 2.53M | 5.39M | 7.92M | 16.1M | 33.1M | 49.93M | 58.72M |
Other Income/Expense | 12.13M | -9.6M | -6.58M | 2.78M | -20.43M | -17.65M | 5.22M | -8.53M | -38.92M | -36.76M |
Pretax Income | 49.71M▲ 0% | 82.63M▲ 66.2% | 25.84M▼ 68.7% | 8.87M▼ 65.7% | 77.75M▲ 776.7% | 86.62M▲ 11.4% | 89.84M▲ 3.7% | 80.82M▼ 10.0% | 39.61M▼ 51.0% | 49.71M▲ 0% |
Pretax Margin % | 13.9% | 15.89% | 4.61% | 2.4% | 10.05% | 7.57% | 6.48% | 3.97% | 1.24% | 1.41% |
Income Tax | 3.89M | 22.36M | 8.17M | 9.18M | 31.69M | 40.88M | 31.99M | 30.89M | 15.53M | 18.73M |
Effective Tax Rate % | 7.82% | 27.06% | 31.61% | 103.54% | 40.76% | 47.19% | 35.61% | 38.22% | 39.21% | 37.67% |
Net Income | 25.8M▲ 0% | 10.84M▼ 58.0% | 14.12M▲ 30.3% | -23.75M▼ 268.3% | 68.92M▲ 390.2% | 45.17M▼ 34.5% | 60.72M▲ 34.4% | 43.15M▼ 28.9% | 22.49M▼ 47.9% | 30.23M▲ 0% |
Net Margin % | 7.21% | 2.08% | 2.52% | -6.42% | 8.91% | 3.95% | 4.38% | 2.12% | 0.71% | 0.86% |
Net Income Growth % | 376.13% | -58.01% | 30.28% | -268.26% | 390.18% | -34.46% | 34.42% | -28.93% | -47.89% | -13.64% |
Net Income (Continuing) | 45.82M | 60.27M | 17.67M | -314K | 46.05M | 45.74M | 57.85M | 49.93M | 24.08M | 30.99M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 176.37M | 226.12M | 169.51M | 114.32M | 62.48M | 15.99M | -203.45M | -198.55M | -220.96M | -222.81M |
EPS (Diluted) | 0.90▲ 0% | 0.29▼ 67.8% | 0.39▲ 34.5% | 1.01▲ 159.0% | 1.52▲ 50.5% | 0.99▼ 34.9% | 1.29▲ 30.3% | 0.90▼ 30.2% | 0.46▼ 48.9% | 0.62▲ 0% |
EPS Growth % | 150.28% | -67.78% | 34.48% | 158.97% | 50.5% | -34.87% | 30.3% | -30.23% | -48.89% | -16.78% |
EPS (Basic) | 1.01 | 0.33 | 0.41 | 1.04 | 1.57 | 1.00 | 1.30 | 0.91 | 0.46 | - |
Diluted Shares Outstanding | 28.66M | 37.91M | 36.4M | 37.45M | 45.4M | 45.6M | 47.07M | 48.22M | 49.37M | 49.05M |
Basic Shares Outstanding | 25.53M | 32.89M | 34.71M | 36.53M | 43.83M | 44.97M | 46.71M | 47.69M | 49.08M | 48.85M |
Dividend Payout Ratio | 40.49% | 163.9% | 437.21% | - | 45.11% | 31.06% | 102.24% | 9.35% | 35.06% | - |
ASTH Balance Sheet
Astrana Health, Inc. (ASTH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 144.16M | 172.86M | 329.07M | 338.58M | 404.46M | 428.13M | 461.51M | 638.5M | 863.31M | 1B |
Cash & Short-Term Investments | 120.92M | 108.02M | 219.73M | 261.17M | 286.51M | 293.59M | 296.31M | 290.83M | 429.47M | 478.38M |
Cash Only | 119.77M | 106.89M | 103.19M | 193.47M | 233.1M | 288.03M | 293.81M | 288.45M | 429.47M | 478.38M |
Short-Term Investments | 1.14M | 1.13M | 116.54M | 67.69M | 53.42M | 5.57M | 2.5M | 2.38M | 0 | 0 |
Accounts Receivable | 20.12M | 57.46M | 98.95M | 60.62M | 99.31M | 119.73M | 147.75M | 324.8M | 407.57M | 500.07M |
Days Sales Outstanding | 20.53 | 40.34 | 64.42 | 59.76 | 46.84 | 38.2 | 38.89 | 58.27 | 46.76 | 43.21 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 75K | 0 | 0 | 14.8M | 17.45M | 22.86M | 26.26M | 25.65M |
Total Non-Current Assets | 346.48M | 340.14M | 399.64M | 478.91M | 462.9M | 538.09M | 471.85M | 716.4M | 1.36B | 1.35B |
Property, Plant & Equipment | 13.81M | 12.72M | 26.38M | 48.46M | 68.63M | 128.98M | 44.57M | 46.88M | 94.43M | 93.48M |
Fixed Asset Turnover | 25.90x | 40.87x | 21.25x | 7.64x | 11.28x | 8.87x | 31.11x | 43.40x | 33.69x | 43.21x |
Goodwill | 189.85M | 185.81M | 238.5M | 239.05M | 246.42M | 269.05M | 278.83M | 419.25M | 863.94M | 874.8M |
Intangible Assets | 0 | 0 | 103.01M | 86.98M | 82.81M | 76.86M | 71.65M | 118.18M | 270.97M | 257.12M |
Long-Term Investments | 37.65M | 53.53M | 29.32M | 80.37M | 42.61M | 42.7M | 32.17M | 48.22M | 25.64M | 232.16M |
Other Non-Current Assets | 1.63M | 1.21M | 2.43M | 19.41M | 22.44M | 4.56M | 2.22M | 63.22M | 100.37M | 48.09M |
Total Assets | 490.64M▲ 0% | 513M▲ 4.6% | 728.71M▲ 42.0% | 817.49M▲ 12.2% | 867.36M▲ 6.1% | 966.21M▲ 11.4% | 933.36M▼ 3.4% | 1.35B▲ 45.2% | 2.22B▲ 63.8% | 2.36B▲ 0% |
Asset Turnover | 0.73x | 1.01x | 0.77x | 0.45x | 0.89x | 1.18x | 1.49x | 1.50x | 1.43x | 1.71x |
Asset Growth % | 2407.53% | 4.56% | 42.05% | 12.18% | 6.1% | 11.4% | -3.4% | 45.16% | 63.75% | 230.15% |
Total Current Liabilities | 109.6M | 72.02M | 105.42M | 114.99M | 114.72M | 148.61M | 218.67M | 365.61M | 615.27M | 745.37M |
Accounts Payable | 27.18M | 4.48M | 6.91M | 9.55M | 5.51M | 10.47M | 9.07M | 15.17M | 3.52M | 221.39M |
Days Payables Outstanding | 33.78 | 4.3 | 5.39 | 10.01 | 3.38 | 4.05 | 2.83 | 3.14 | 0.45 | 12.81 |
Short-Term Debt | 5.54M | 40.26K | 9.5M | 10.89M | 780K | 619K | 19.5M | 9.38M | 55.67M | 55.42M |
Deferred Revenue (Current) | 250K | 9.02M | 8.89M | 12.99M | 16.8M | 531K | 744K | 1.61M | 0 | 0 |
Other Current Liabilities | 68.99M | 41.75M | 61.96M | 67.09M | 65.89M | 113.24M | 164M | 257.74M | 556.08M | 439.44M |
Current Ratio | 1.32x | 2.40x | 3.12x | 2.94x | 3.53x | 2.88x | 2.11x | 1.75x | 1.40x | 1.35x |
Quick Ratio | 1.32x | 2.40x | 3.12x | 2.94x | 3.53x | 2.88x | 2.11x | 1.75x | 1.40x | 1.35x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 30.4 |
Total Non-Current Liabilities | 44.72M | 34.32M | 262.23M | 257.35M | 242M | 259.06M | 303.92M | 475.12M | 1.05B | 1.04B |
Long-Term Debt | 0 | 13M | 232.17M | 230.21M | 182.92M | 203.39M | 258.94M | 425.3M | 990.9M | 979.76M |
Capital Lease Obligations | 520.26K | 517.26K | 11.79M | 16.18M | 14.17M | 21.19M | 37.32M | 31.26M | 31.55M | 120.44M |
Deferred Tax Liabilities | 24.92M | 19.62M | 18.27M | 10.96M | 30.14M | 14.22M | 4.07M | 4.55M | 5.49M | 19.91M |
Other Non-Current Liabilities | 19.28M | 1.19M | 0 | 0 | 14.78M | 20.26M | 3.59M | 14M | 17.11M | 18.83M |
Total Liabilities | 154.32M | 106.34M | 367.65M | 372.34M | 356.72M | 407.67M | 522.59M | 840.73M | 1.66B | 1.78B |
Total Debt | 6.25M | 13.66M | 256.55M | 260.56M | 200.98M | 229.36M | 321.01M | 471.84M | 1.08B | 1.07B |
Net Debt | -113.52M | -93.23M | 153.36M | 67.08M | -32.11M | -58.66M | 27.21M | 183.38M | 648.66M | 586.81M |
Debt / Equity | 0.02x | 0.03x | 0.71x | 0.59x | 0.39x | 0.41x | 0.78x | 0.92x | 1.93x | 1.84x |
Debt / EBITDA | 0.11x | 0.12x | 5.06x | 10.66x | 1.74x | 1.88x | 3.14x | 4.02x | 8.68x | 7.56x |
Net Debt / EBITDA | -2.00x | -0.84x | 3.02x | 2.75x | -0.28x | -0.48x | 0.27x | 1.56x | 5.22x | 4.17x |
Interest Coverage | 624.81x | 148.41x | 6.46x | 4.51x | 15.41x | 11.94x | 6.58x | 3.44x | 1.57x | 1.61x |
Total Equity | 336.31M▲ 0% | 406.66M▲ 20.9% | 361.06M▼ 11.2% | 445.15M▲ 23.3% | 510.64M▲ 14.7% | 558.55M▲ 9.4% | 410.77M▼ 26.5% | 514.17M▲ 25.2% | 558.33M▲ 8.6% | 577.46M▲ 0% |
Equity Growth % | 3832.9% | 20.92% | -11.21% | 23.29% | 14.71% | 9.38% | -26.46% | 25.17% | 8.59% | 41.9% |
Book Value per Share | 11.73 | 10.73 | 9.92 | 11.89 | 11.25 | 12.25 | 8.73 | 10.66 | 11.31 | 11.77 |
Total Shareholders' Equity | 159.95M | 180.55M | 191.55M | 330.82M | 448.17M | 542.56M | 614.22M | 712.72M | 779.29M | 800.27M |
Common Stock | 32.3K | 34.58K | 36K | 42K | 45K | 47K | 47K | 48K | 49K | 49K |
Retained Earnings | 1.73M | 17.79M | 31.91M | 69.77M | 137.25M | 182.42M | 243.13M | 286.28M | 308.38M | 322.71M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 176.37M | 226.12M | 169.51M | 114.32M | 62.48M | 15.99M | -203.45M | -198.55M | -220.96M | -222.81M |
ASTH Cash Flow Statement
Astrana Health, Inc. (ASTH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 53.07M | 26.1M | 13.67M | 46.16M | 70.33M | 82.13M | 68.23M | 52.2M | 114.6M | 166.03M |
Operating CF Margin % | 14.84% | 5.02% | 2.44% | 12.47% | 9.09% | 7.18% | 4.92% | 2.57% | 3.6% | - |
Operating CF Growth % | 2985.82% | -50.82% | -47.62% | 237.62% | 52.36% | 16.77% | -16.93% | -23.49% | 119.54% | 604.26% |
Net Income | 25.8M | 10.84M | 17.67M | 122.08M | 46.05M | 45.74M | 57.85M | 49.93M | 24.08M | 30.23M |
Depreciation & Amortization | 19.08M | 19.3M | 18.28M | 18.35M | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M | 54.38M |
Stock-Based Compensation | 0 | 0 | 1.55M | 3.38M | 6.75M | 16.1M | 22.04M | 34.54M | 38.6M | 11.38M |
Deferred Taxes | -20.68M | -8.35M | -6.8M | 396K | 7.67M | -14.28M | -12.44M | -4.25M | -4.29M | -2.02M |
Other Non-Cash Items | 42.15M | 157.26M | 5.75M | -102.08M | 25.98M | 18.98M | 6.42M | 7.67M | 13.56M | 40.09M |
Working Capital Changes | 15.98M | -63.05M | -22.77M | 4.04M | -33.64M | -1.96M | -23.39M | -63.61M | -3.1M | 31.4M |
Change in Receivables | 10.7M | -28.63M | -5.8M | 3.01M | -21.63M | -33.97M | -20.57M | -11.1M | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | -7.71M | -2.11M | 27.61M | 12.15M | 0 | 0 | 0 |
Change in Payables | -1.81M | -22.67M | -4.39M | 15.82M | 4.11M | -2.52M | -498K | -30.43M | 0 | 0 |
Cash from Investing | 6.73M | -25.76M | -180.63M | 95.49M | 16.54M | -7.11M | -65.52M | -192.4M | -539M | -539.42M |
Capital Expenditures | -2.08M | -1.17M | -1.04M | -1.16M | -19.22M | -22.94M | -28.53M | -8.03M | -10.11M | -11.04M |
CapEx % of Revenue | 0.58% | 0.23% | 0.19% | 0.31% | 2.48% | 2% | 2.06% | 0.39% | 0.32% | 0.31% |
Acquisitions | 0 | -16.68M | -53M | 31.42M | -3.9M | -18.46M | -7.54M | -156.13M | -548.6M | -548.58M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 26.8M | -7.5M | -11.19M | 16.41M | 56K | 4.47M | -23.8M | -25.74M | 4.61M | 5.17M |
Cash from Financing | -14.98M | -11.2M | 163.33M | -51.7M | -47.75M | -20.09M | 3.42M | 135.15M | 569.35M | 597.53M |
Debt Issued (Net) | 4.9M | 7.41M | 234.48M | -9.61M | -58.69M | -828K | 79.17M | 152.71M | 604.81M | 645.66M |
Equity Issued (Net) | -425.28K | -850.97K | -6.82M | 10.27M | 43.46M | -9.25M | -8.67M | -937K | -15.43M | -2.4M |
Dividends Paid | -10.45M | -17.76M | -61.72M | -51.32M | -31.09M | -14.03M | -62.07M | -4.04M | -7.88M | -2.53M |
Share Repurchases | -3.18M | -5.05M | -7.57M | -537K | -5.74M | -9.25M | -10.19M | -937K | -15.43M | -2.1M |
Other Financing | -9M | 323 | -2.62M | -1.04M | -1.42M | 4.02M | -5.01M | -12.59M | -12.15M | -43.2M |
Net Change in Cash | 110.5M▲ 0% | -12.88M▼ 111.7% | -3.63M▲ 71.8% | 89.96M▲ 2580.3% | 39.13M▼ 56.5% | 54.93M▲ 40.4% | 6.13M▼ 88.8% | -5.05M▼ 182.5% | 144.94M▲ 2969.6% | 222.34M▲ 0% |
Free Cash Flow | 50.99M▲ 0% | 24.93M▼ 51.1% | 12.63M▼ 49.3% | 45M▲ 256.3% | 51.11M▲ 13.6% | 59.19M▲ 15.8% | 39.7M▼ 32.9% | 44.17M▲ 11.3% | 104.49M▲ 136.6% | 154.99M▲ 0% |
FCF Margin % | 14.25% | 4.8% | 2.25% | 12.15% | 6.6% | 5.17% | 2.86% | 2.17% | 3.28% | 4.4% |
FCF Growth % | 2526.63% | -51.1% | -49.34% | 256.26% | 13.58% | 15.8% | -32.93% | 11.26% | 136.58% | 197.39% |
FCF per Share | 1.78 | 0.66 | 0.35 | 1.20 | 1.13 | 1.30 | 0.84 | 0.92 | 2.12 | 3.16 |
FCF Conversion (FCF/Net Income) | 2.06x | 2.41x | 0.97x | -1.94x | 1.02x | 1.82x | 1.12x | 1.21x | 5.10x | 5.13x |
Interest Paid | 51.04K | 462K | 4.26M | 8.51M | 4.16M | 6.67M | 14.25M | 30.42M | 0 | 0 |
Taxes Paid | 24.36M | 23.64M | 20.2M | 62M | 37.2M | 47.31M | 56.57M | 43.94M | 0 | 0 |
ASTH Key Ratios
Astrana Health, Inc. (ASTH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 14.96% | 2.92% | 3.68% | -5.89% | 14.42% | 8.45% | 12.53% | 9.33% | 4.19% | 5.43% |
Return on Invested Capital (ROIC) | 25.36% | 25.8% | 5.87% | 0.89% | 14.86% | 15.98% | 13.53% | 11.8% | 6.18% | 6.18% |
Gross Margin | 17.89% | 26.83% | 16.56% | 5.86% | 22.97% | 17.43% | 15.5% | 13.34% | 9.3% | 9.31% |
Net Margin | 7.21% | 2.08% | 2.52% | -6.42% | 8.91% | 3.95% | 4.38% | 2.12% | 0.71% | 0.86% |
Debt / Equity | 0.02x | 0.03x | 0.71x | 0.59x | 0.39x | 0.41x | 0.78x | 0.92x | 1.93x | 1.84x |
Interest Coverage | 624.81x | 148.41x | 6.46x | 4.51x | 15.41x | 11.94x | 6.58x | 3.44x | 1.57x | 1.61x |
FCF Conversion | 2.06x | 2.41x | 0.97x | -1.94x | 1.02x | 1.82x | 1.12x | 1.21x | 5.10x | 5.13x |
Revenue Growth | 712.16% | 45.33% | 7.83% | -33.96% | 109.03% | 47.84% | 21.19% | 46.72% | 56.39% | 56.69% |
Related:ASTH Dividend History·ASTH Revenue History·ASTH Price History·ASTH P/E History·ASTH Financial Ratios·ASTH Institutional Holders
ASTH SEC Filings & Documents
Astrana Health, Inc. (ASTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
ASTH Frequently Asked Questions
Astrana Health, Inc. (ASTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Astrana Health, Inc. (ASTH) reported $3.53B in revenue for fiscal year 2025. This represents a 7906% increase from $44.0M in 2015.
Astrana Health, Inc. (ASTH) grew revenue by 56.4% over the past year. This is strong growth.
Yes, Astrana Health, Inc. (ASTH) is profitable, generating $30.2M in net income for fiscal year 2025 (0.7% net margin).
Dividend & Returns
Yes, Astrana Health, Inc. (ASTH) pays a dividend with a yield of 0.41%. This makes it attractive for income-focused investors.
Astrana Health, Inc. (ASTH) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
Astrana Health, Inc. (ASTH) generated $155.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.